Press Release: Nuwellis to Convene Pediatric Medical & Nursing Advisory Board to Advance Development of Vivian(TM) Pediatric CRRT System

MINNEAPOLIS, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardiorenal conditions, today announced that it will convene a Medical & Nursing Advisory Board on November 18--19, 2026, to support the continued development of Vivian(TM), the Company's next-generation pediatric continuous renal replacement therapy (CRRT) platform. Vivian is under development for children as small as 2.5kg and it incorporates multiple fluid management therapies in one platform. "Vivian is being purpose-built around the unique clinical and operational needs of pediatric patients and the clinicians who care for them," said Mike McCormick, Nuwellis President and Chief Executive Officer. "Direct provider and nurse input at this critical stage provides the opportunity to validate the progress we have made and ensure that the voice of the customer continues to shape the system as we move forward. We believe the advisory board is an important development milestone within our pediatric strategy and reflects our commitment to building solutions that address unmet needs across the continuum.